Inhibition Of IL-13 Cytokine-Induced Responses Do Not Affect COVID Incidence

The IL-13 inflammatory pathway is known to potentiate atopic disease entities including asthma and atopic dermatitis (AD). More recently, IL-13 signaling has been associated with COVID-19 viral propagation. Dupilumab is commonly used to treat AD through inhibition of IL-13, but the immunosuppressive effect of biologics is still being explored with respect to COVID-19 incidence and severity. We hypothesized that IL-13 inhibition in dupilumab AD patients may decrease incidence of COVID-19 infection compared to non-dupilumab AD patients.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research